Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies

References

• HorwichAHugossonJde ReijkeTWiegelTFizaziKKatajaVPanel MembersEuropean Society for Medical OncologyProstate cancer: ESMO Consensus Conference Guidelines 2012Ann Oncol20132451141116223303340
   PubMed Web of Science ®Google Scholar
• SiegelRMaJZouZJemalACancer statistics, 2014CA Cancer J Clin201464192924399786
   PubMed Web of Science ®Google Scholar
• NCCN guidelines version 2.2016 prostate cancer2016Fort Washington, PA 19034, USANational Comprehensive Cancer Network® Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed April 15, 2016
   Google Scholar
• HorwichAParkerCde ReijkeTKatajaVESMO Guidelines Working GroupProstate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201324Suppl 6vi106vi11423813930
   PubMed Web of Science ®Google Scholar
• MottetNBellmuntJBriersEEAU Guidelines on prostate cancer2015European Association of Urology Available from: http://uroweb.org/wp-content/uploads/EAU-Guidelines-Prostate-Cancer-2015-v2.pdfAccessed February 18, 2016
   Google Scholar
• HeidenreichABastianPJBellmuntJEAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancerEur Urol201465246747924321502
   PubMed Web of Science ®Google Scholar
• LabrieFBelangerALuu-TheVGonadotropin-releasing hormone agonists in the treatment of prostate cancerEndocr Rev200526336137915867098
   PubMed Web of Science ®Google Scholar
• MottetNBellmuntJBollaMEAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancerEur Urol201159457258321315502
   PubMed Web of Science ®Google Scholar
• BertagliaVTucciMFioriCEffects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancerClin Genitourin Cancer2013113325330.e32123531429
   PubMed Web of Science ®Google Scholar
• CrawfordEDMoulJWSartorOShoreNDExtended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dlExpert Opin Drug Metab Toxicol20151191465147426293510
   PubMed Web of Science ®Google Scholar
• KlotzLO’CallaghanCDingKNadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration- resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADTJ Clin Oncol201533101151115625732157
   PubMed Web of Science ®Google Scholar
• MoroteJOrsolaAPlanasJRedefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapyJ Urol20071784 Pt 11290129517698136
   PubMed Web of Science ®Google Scholar
• PerachinoMCavalliVBraviFTestosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?BJU Int2010105564865119747358
   PubMed Web of Science ®Google Scholar
• OefeleinMGFengAScolieriMJRicchiuttiDResnickMIReassessment of the definition of castrate levels of testosterone: implications for clinical decision makingUrology20005661021102411113751
   PubMed Web of Science ®Google Scholar
• PersadRLeuprorelin acetate in prostate cancer: a European updateInt J Clin Pract200256538939612137449
   PubMed Web of Science ®Google Scholar
• AbbVie IncLupron-Depot^® (leuprolide acetate for depot suspension) [prescribing information]North Chicago, ILAbbVie, Inc2016 Available from: http://www.rxabbvie.com/pdf/lupronuro_pi.pdfAccessed July 8, 2016
   Google Scholar
• Tolmar Pharmaceuticals IncEligard-leuprolide acetate [prescribing information]Fort Collins, COTolmar Pharmaceuticals, Inc2014 Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b78d1919-9dee-44fa-90f9-e0a26d32481dAccessed April 14, 2016
   Google Scholar
• SartorODineenMKPerez-MarrenoRChuFMCarronGJTylerRCAn eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancerUrology200362231932312893343
   PubMed Web of Science ®Google Scholar
• ChuFMJaysonMDineenMKPerezRHarkawayRTylerRCA clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancerJ Urol200216831199120312187267
   PubMed Web of Science ®Google Scholar
• SharifiRSolowayMClinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study GroupJ Urol1990143168712104638
   PubMed Web of Science ®Google Scholar
• SpitzAYoungJMLarsenLMattia-GoldbergCDonnellyJChwaliszKEfficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancerProstate Cancer Prostatic Dis2012151939922025196
   PubMed Web of Science ®Google Scholar
• BraeckmanJMichielsenDEfficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard®/Depo-Eligard®) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional studyArch Med Sci201410347748325097577
   PubMed Web of Science ®Google Scholar
• CrawfordEDSartorOChuFPerezRKarlinGGarrettJSA 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancerJ Urol2006175253353616406989
   PubMed Web of Science ®Google Scholar
• TunnUWA 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patientsBMC Urol2011111521801354
   PubMed Web of Science ®Google Scholar
• SharifiRKnollLDSmithJKramolowskyELeuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancerUrology19985122712769495710
   PubMed Web of Science ®Google Scholar
• OkenMMCreechRHTormeyDCToxicity and response criteria of the Eastern Cooperative Oncology GroupAm J Clin Oncol1982566496557165009
   PubMed Web of Science ®Google Scholar
• Prostate Cancer Trialists’ Collaborative GroupMaximum androgen blockade in advanced prostate cancer: an overview of the randomised trialsLancet200035592141491149810801170
   PubMed Web of Science ®Google Scholar
• DjavanBEasthamJGomellaLTestosterone in prostate cancer: the Bethesda consensusBJU Int2012110334435222129242
   PubMed Web of Science ®Google Scholar
• ResnickMJLacchettiCPensonDFProstate cancer survivorship care guidelines: American Society of Clinical Oncology practice guideline endorsementJ Oncol Pract2015113e445e44925829527
   PubMed Web of Science ®Google Scholar